XML 48 R40.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Reporting (Tables)
9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Schedule of Business Segment Information

The Company’s business segment information was as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Proteomics

 

$

34,565

 

 

$

14,008

 

 

$

98,954

 

 

$

47,296

 

Genomics

 

 

10,404

 

 

 

11,359

 

 

 

28,760

 

 

 

30,856

 

Total revenue

 

$

44,969

 

 

$

25,367

 

 

$

127,714

 

 

$

78,152

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from operations:

 

 

 

 

 

 

 

 

 

 

 

 

Proteomics

 

$

(10,210

)

 

$

(7,106

)

 

$

(48,485

)

 

$

(16,297

)

Genomics

 

 

1,925

 

 

 

301

 

 

 

2,681

 

 

 

41

 

Corporate expenses

 

 

(16,013

)

 

 

(10,703

)

 

 

(59,217

)

 

 

(31,877

)

Restructuring and related charges

 

 

(2,341

)

 

 

(1,998

)

 

 

(12,374

)

 

 

(5,415

)

Transaction and integration expenses

 

 

(5,079

)

 

 

(1,666

)

 

 

(25,024

)

 

 

(1,666

)

Total loss from operations

 

$

(31,718

)

 

$

(21,172

)

 

$

(142,419

)

 

$

(55,214

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation & amortization:

 

 

 

 

 

 

 

 

 

 

 

 

Proteomics

 

 

1,940

 

 

 

3,420

 

 

$

7,193

 

 

$

9,932

 

Genomics

 

 

378

 

 

 

373

 

 

 

1,125

 

 

 

703

 

Corporate

 

 

1,540

 

 

 

193

 

 

 

4,590

 

 

 

639

 

Total depreciation & amortization

 

$

3,858

 

 

$

3,986

 

 

$

12,908

 

 

$

11,274